FDA clears expanded label for Cerus Intercept Blood System

• The FDA approves the use of Cerus' (NASDAQ:CERS +7.6%) Intercept Blood System for platelets, the first pathogen reduction system to treat single donor apheresis platelets. Three days ago, the agency approved the system for plasma.
• Previously: Cerus +20.3% AH; FDA approves Intercept for plasma (Dec. 16, 2014)